Role of soluble and cell surface molecules in the pathogenesis of autoimmune skin diseases

Clinical and Experimental Rheumatology

Volumn 24, Issue SUPPL. 40, 2006, Pages

  Drosera, M ^a   Facchetti, F ^b   Landolfo, S ^c   Mondini, M ^c   Nyberg, F ^d   Parodi, A ^a   Santoro, A ^b   Zampieri, S ^e   Doria, Andrea ^e  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d DANDERYD HOSPITAL   (Sweden)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti IFI16 autoantibodies; Autoimmune diseases; CAMs; Cutaneous lupus erythematosus; DNase; E selection; Systemic sclerosis; TNF , IFN , plasmacytoid monocytes interferon producing cells (PM IPC); UV

Indexed keywords

CELL ADHESION MOLECULE; DEOXYRIBONUCLEASE; DNA; EFALIZUMAB; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; AUTOIMMUNE SKIN DISEASE; CYTOKINE RELEASE; DNA DEGRADATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS CELL; GENETIC PREDISPOSITION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; KERATINOCYTE; LUPUS ERYTHEMATOSUS; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; RECEPTOR DOWN REGULATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN LUPUS ERYTHEMATOSUS; ULTRAVIOLET RADIATION; VASCULITIS;

APOPTOSIS; AUTOIMMUNE DISEASES; CELL ADHESION MOLECULES; DEOXYRIBONUCLEASES; HUMANS; INTERFERONS; LUPUS ERYTHEMATOSUS, CUTANEOUS; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645028904     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. WANG B, FUJISAWA H, ZHUANG L et al.: Depressed Langerhans cells migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75. J Immunol 1997; 159: 6148-55.
2. TRAUTMANN A, AKDIS M, KLEEMANN D et al.: T cell-mediated Fas-induced keratinocyte apoptosis play a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000; 106: 25-35.
3. STUDNICKA-BENKE A, STEINER G, PETERA P SMOLEN JS: Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1067-74.
4. ARINGER M, FEIERL E, STEINER G et al.: Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002; 11: 102-8.
5. ARINGER M, SMOLEN JS: Cytokine expression in lupus kidneys. Lupus 2005; 14: 13-8.
6. SONTHEIMER RD, THOMAS JR, GILLIAM JN: Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115: 1409-15.
7. SONTHEIMER RD: Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by a characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmunity Rev 2005; 4: 253-63.
8. BRIANI C, ZARA G, RONDINONE R et al.: Thalidomide neurotoxicity. Prospective study in patients with lupus erythematosus. Neurology 2004; 62: 2288-90.
9. ZAMPIERI S, ALAIBAC M, IACCARINO L et al.: TNF-α is expressed in refractory skin lesions from subacute cutaneous lupus erythematosus patients. Ann Rheum Dis 2005; Aug 11; [Epub ahead of print].
10. CLANCY RM, BACCKER CB, YIN X et al.: Genetic association of cutaneous neonatal lupus with HLA Class II and tumor necrosis factor α. Implication for pathogenesis. Arthitis Rheum 2004; 50: 2598-603.
11. ARINGER M, GRANINGER WB, STEINER G, SMOLEN JS: Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161-9.
12. HIEPE F, BRUNS A, FEIST E, BURMESTER G-R: Successful treatment of a patient suffering from a refractory subacute cutaneous lupus erythematosus (SCLE) with blockers of tumor necrosis factor A. Arthritis Rheum 2004; 50: S413.
13. CSISZAR A, NAGY G, GERGELY P, POZSONYI T, POCSIK E: Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000; 122: 464-70.
14. SOLANS R, BOSCH JA, ESTEBAN I, VILARDELL M: Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 2004; 22: 625-8.
15. ASEFA B, KLARMANN KD, COPELAND NG, GILBERT DJ, JENKINS NA, KELLER JR: The interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle regulation and differentiation. Blood Cells Mol Dis 2004; 32: 155-67.
16. CHOUBEY D, KOTZIN BL: Interferon-inducible p202 in the susceptibility to systemic lupus. Front Biosci 2002; 7: e252-62.
17. SEELIG HP, EHRFELD H, RENZ M: Interferon-gamma-inducible protein p16. A new target of antinuclear antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1672-83.
18. UCHIDA K, AKITA Y, MATSUO K et al.: Identification of specific autoantigens in Sjögren's syndrome by SEREX. Immunology 2005; 116: 53-63.
19. MEDSGER TA Jr, SILMAN AJ, STEEN VD et al.: A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
20. GRASSI W, MEDICO PD, IZZO F, CERVINI C: Microvascular involvement in systemic sclerosis: capillaroscopic findings. Semin Arthritis Rheum 2001; 30: 397-402.
21. GARIGLIO M, AZZIMONTI B, PAGANO M et al.: Immunohistochemical expression analysis of the human interferon-inducible gene IFI16, a member of the HIN200 family, not restricted to hematopoietic cells. J Interferon Cytokine Res 2002; 22: 815-21.
22. RAFFAELLA R, GIOIA D, DE ANDREA M et al.: The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp Cell Res 2004; 293: 331-45.
23. THEOFILOPOULOS AN, BACCALA R, BEUTLER B, KONO DH: Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-36.
24. BENNETT L, PALUCKA AK, ARCE E et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23.
25. FARKAS L, BEISKE K, LUND-JOHANSEN F, BRANDTZAEG P, JAHNSEN FL: Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159: 237-43.
26. FACCHETTI F, BODEN G, DE WOLF-PEETERS C, VANDAELE R, DEGREEF H, DESMET VJ: Plasmacytoid monocytes in Jessner's lymphocytic infiltration of the skin. Am J Dermatopathol 1990; 12: 363-9.
27. LOVGREN T, ELORANTA ML, BAVE U, ALM GV, RONNBLOM L: Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50: 1861-72.
28. WENZEL J, WORENKAMPER E, FREUTEL et al.: Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005; 205: 435-42.
29. SANTORO A, MAJORANA A, ROVERSI L et al.: Recruitment of dendritic cells in oral lichen planus. J Pathol 2005; 205: 426-34.
30. SUOMELA S, CAO L, BOWCOCK A, SAARIALHO-KERE U: Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol 2004; 122: 717-21.
31. RISSOAN MC, DUHEN T, BRIDON JM et al.: Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 2002; 100: 3295-303.
32. FACCHETTI F, VERMI W, MASON D, COLONNA M: The plasmacytoid monocyte/interferon producing cells. Virchows Arch 2003; 443: 703-17.
33. SFIKAKIS P, TSOKOS G: Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations. Clin Exp Rheumatol 1995; 13: 763-77.
34. NYBERG F, STEPHANSSON E: The role of T-cells and adhesion molecules in cutaneous lupus erythematosus. In: KUHN A, LEHMANN P, RUZICKA T (Eds.): Cutaneous Lupus Erythematosus. Berlin, Heidelberg, New York, Springer Verlag 2004: 267-82.
35. STEVENS G, BERGSTRESSER P: Photoimmunology. In: HAWK J (Ed.): Photodermatology. New York, Arnold; 1999: 53-68.
36. BENNION SD, MIDDLETON M, DAVID-BAJAR K, BRICE S, NORRIS DA: In three types of interface dermatitis, different patterns of expression of intercellular adhesion molecule-1 indicate different triggers of disease. J Invest Dermatol 1995; 105: 71S-9S.
37. NYBERG F, HASAN T, SKOGLUND C, STEPHANSSON E: Early events in ultraviolet light-induced skin lesions in lupus erythematosus: Expression patterns of adhesion molecules ICAM-1, VCAM-1 and E-selectin. Acta Derm Venereol 1999; 79: 431-6.
38. KUHN A, SONNTAG M, SUNDERKÖTTER C, LEHMANN P, VESTWEBER D, RUZICKA T: Upregulation of epidermal surface molecule expression in primary and ultraviolet-induced lesions of lupus erythematosus tumidus. Br J Dermatol 2002; 146: 801-9.
39. KUHN A, SONNTAG M, LEHMANN P, MEGAHED M, VESTWEBER D, RUZICKA T: Characterization of the inflammatory infiltrate and expression of endothelial cell adhesion molecules in lupus erythematosus tumidus. Arch Dermatol Res 2002; 294: 6-13.
40. NYBERG F, ACEVEDO F, STEPHANSSON E: Different patterns of soluble adhesion molecules in systemic and cutaneous lupus erythematosus. Experimental Dermatology 1997; 6: 230-5.
41. NYBERG F, STEPHANSSON E: Elevated soluble E-selectin in cutaneous lupus erythematosus. In: MALLIA C, UITTO J (Eds.): Rheumaderm, Current Issues in Rheumatology and Dermatology. New York: Kluwer Academic/Plenum Publishers; 1999: 153-9.
42. KOIDE M, FURUKAWA F, WAKITA H, TOKURA Y, MUSO E, TAKIGAWA M: Soluble form of vascular cell adhesion molecule-1 in systemic lupus erythematosus and discoid lupus erythematosus. J Dermatol Science 1996; 12: 73-5.
43. DAHLMAN-GHOZLAN K, HEILBORN J, STEPHANSSON E: Circulating levels of soluble E-selectin, ICAM-1 and VCAM-1 in bullous pemphigoid during low-dose methotrexate therapy. A prospective study. Exp Dermatol 2000; 9: 336-40.
44. DAHLMAN-GHOZLAN K, ORTONNE J, HEILBORN J, STEPHANSSON E: Altered tissue expression pattern of cell adhesion molecules, ICAM-1, E-selectin and VCAM-1 in bullous pemphigoid during metothrexate therapy. Exp Dermatol 2004; 13: 65-9.
45. TREFZER U, KRUTMANN J: Adhesion molecules as molecular targets in ultraviolet B radiation (290-315 nm)-induced immunomodulation: UVB radiation effects on the expression of intercellular adhesion molecule-1 in human cells. In: KRUTMANN J and ELMETS C (Eds.): Photoimmunology. Berlin, Germany: Blackwell Science Ltd; 1995: 77-89.
46. BREY R, AMATO A, KAGAN-HALLET K, RHINE C, STALLWORTH C: Anti-intercellular adhesion molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice. Lupus 1997; 6: 645-51.
47. BULLARD D: Adhesion molecules in inflammatory diseases- insights from knockout mice. Immunol Res 2002; 26: 27-33.
48. NAMAZI M: Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004; 13: 337-9.
49. MACANOVIC M, LACHMANN PJ: Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997; 108: 220-6.
50. NAPIREI M, KARSUNKY H, ZEVNIK B, STEPHAN H, MANNHERZ HG, MOROY T: Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000; 25: 177-81.
51. YEH TM, CHANG HC, LIANG CC, WU JJ, LIU MF: Desoxyribonuclease-inhibitory antibodies in systemic lupus erythematosus. J Biomed Sci 2003; 10: 544-51.